Chenglin Mu

450 total citations
15 papers, 317 citations indexed

About

Chenglin Mu is a scholar working on Molecular Biology, Pharmacology and Complementary and alternative medicine. According to data from OpenAlex, Chenglin Mu has authored 15 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pharmacology and 5 papers in Complementary and alternative medicine. Recurrent topics in Chenglin Mu's work include Traditional Chinese Medicine Analysis (4 papers), Advanced Nanomaterials in Catalysis (3 papers) and Pharmacological Effects of Natural Compounds (3 papers). Chenglin Mu is often cited by papers focused on Traditional Chinese Medicine Analysis (4 papers), Advanced Nanomaterials in Catalysis (3 papers) and Pharmacological Effects of Natural Compounds (3 papers). Chenglin Mu collaborates with scholars based in China, Kazakhstan and United States. Chenglin Mu's co-authors include Yingqiu Xie, Xugang Li, Amr Amin, Qian Wang, Baode Chen, Zhiwei Zhang, Xia Liu, Cuiping Ma, Qinglei Sun and Ashfaq Ahmad and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Chenglin Mu

15 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chenglin Mu China 9 130 51 51 50 43 15 317
Qin Qiu China 9 112 0.9× 37 0.7× 39 0.8× 46 0.9× 31 0.7× 27 366
Min Yin China 15 167 1.3× 23 0.5× 38 0.7× 45 0.9× 40 0.9× 29 418
Hamid El Amri Morocco 11 107 0.8× 57 1.1× 19 0.4× 47 0.9× 57 1.3× 20 375
Anand Srivastava India 13 168 1.3× 26 0.5× 71 1.4× 26 0.5× 86 2.0× 56 498
Laboni Mondal India 11 161 1.2× 34 0.7× 28 0.5× 13 0.3× 35 0.8× 13 403
Pantea Mohammadi Iran 11 131 1.0× 32 0.6× 33 0.6× 26 0.5× 23 0.5× 26 370
Trilochan Satapathy India 13 123 0.9× 16 0.3× 45 0.9× 33 0.7× 79 1.8× 83 470
Hongyuan Shen Singapore 10 177 1.4× 90 1.8× 25 0.5× 24 0.5× 30 0.7× 28 460
Ashwani Sharma India 12 109 0.8× 20 0.4× 26 0.5× 14 0.3× 37 0.9× 19 372
Chih-Chun Wen Taiwan 10 140 1.1× 29 0.6× 104 2.0× 67 1.3× 54 1.3× 12 446

Countries citing papers authored by Chenglin Mu

Since Specialization
Citations

This map shows the geographic impact of Chenglin Mu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenglin Mu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenglin Mu more than expected).

Fields of papers citing papers by Chenglin Mu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenglin Mu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenglin Mu. The network helps show where Chenglin Mu may publish in the future.

Co-authorship network of co-authors of Chenglin Mu

This figure shows the co-authorship network connecting the top 25 collaborators of Chenglin Mu. A scholar is included among the top collaborators of Chenglin Mu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenglin Mu. Chenglin Mu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Tu, Xiaoxuan, Yi Zheng, Chenglin Mu, et al.. (2024). S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. Journal of Experimental & Clinical Cancer Research. 43(1). 72–72. 8 indexed citations
2.
Mu, Chenglin, et al.. (2024). Deer antler extract-nanoparticles exhibit co-nanozyme activity and targeting of prostate cancer cells. Journal of Functional Foods. 115. 106089–106089. 2 indexed citations
3.
Li, Dehui, et al.. (2023). Recent Advances in Chinese and Western Medicine for Cancer-related Fatigue: A Review. 2(4). 206–215. 1 indexed citations
4.
Mu, Chenglin, et al.. (2022). Honghua extract mediated potent inhibition of COVID-19 host cell pathways. Scientific Reports. 12(1). 14296–14296. 10 indexed citations
5.
Liu, Yu, Chenglin Mu, Dongdong Du, et al.. (2022). Alkaline stress reduces root waving by regulating PIN7 vacuolar transport. Frontiers in Plant Science. 13. 1049144–1049144. 3 indexed citations
6.
Chen, Baode, et al.. (2022). The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis. Frontiers in Immunology. 13. 891268–891268. 28 indexed citations
7.
Fan, Haiyan, Qinglei Sun, Kanat Dukenbayev, et al.. (2022). Carbon nanoparticles induce DNA repair and PARP inhibitor resistance associated with nanozyme activity in cancer cells. Cancer Nanotechnology. 13(1). 12 indexed citations
8.
Ahmad, Ashfaq, et al.. (2021). Omicron N501Y mutation among SARS-CoV-2 lineages: In silico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine. Travel Medicine and Infectious Disease. 45. 102242–102242. 26 indexed citations
9.
Sun, Fang, Chenglin Mu, Hang Fai Kwok, et al.. (2021). Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19. International Journal of Biological Sciences. 17(9). 2348–2355. 30 indexed citations
10.
11.
12.
13.
Zhang, Guanhua, Qi Wang, Xin Liu, et al.. (2020). An integrated approach to uncover quality markers of Traditional Chinese medicine underlying chemical profiling, network target selection and metabolomics approach: Guan-Xin-Jing capsule as a model. Journal of Pharmaceutical and Biomedical Analysis. 190. 113413–113413. 8 indexed citations
14.
Mu, Chenglin, et al.. (2020). Potential compound from herbal food of Rhizoma Polygonati for treatment of COVID-19 analyzed by network pharmacology: Viral and cancer signaling mechanisms. Journal of Functional Foods. 77. 104149–104149. 106 indexed citations
15.
Mu, Chenglin, et al.. (2020). Dataset of potential Rhizoma Polygonati compound-druggable targets and partial pharmacokinetics for treatment of COVID-19. SHILAP Revista de lepidopterología. 33. 106475–106475. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qin Qiu Breakdown of academic impact, for papers by Min Yin Breakdown of academic impact, for papers by Hamid El Amri Breakdown of academic impact, for papers by Anand Srivastava Breakdown of academic impact, for papers by Laboni Mondal Breakdown of academic impact, for papers by Pantea Mohammadi Breakdown of academic impact, for papers by Trilochan Satapathy Breakdown of academic impact, for papers by Hongyuan Shen Breakdown of academic impact, for papers by Ashwani Sharma Breakdown of academic impact, for papers by Chih-Chun Wen
Rankless by CCL
2026